Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2016

View Archived Issues

Lilly initiates phase I trial of LY-3214996 alone and in combination for advanced cancers

Novel MYH7 mutation causes Laing distal myopathy

EMA grants orphan designation to Iomab-B

EMA grants PRIME access to Atara's EBV-CTL

The Medicines Company reports positive results for PCSK-9si trial

Antegrin Therapeutics and Cascadia Therapeutics merge to form Indalo Therapeutics

EMA gives orphan drug designation to gene therapy program ABO-102

Corbus Pharmaceuticals' Resunab wins European orphan drug designation for CF

Lilly to contribute cancer research data to NCI's Blood Profiling Atlas

Rational Vaccines reports results from phase I trial of HSV vaccine

Bavarian Nordic begins phase II study of RSV vaccine

Adaptimmune Therapeutics initiates phase I study of T-cell therapy in urothelial cancer

Takeda Pharmaceutical patents enteropeptidase inhibitors

Shenyang Sunshine Pharmaceutical discloses EGLN1 inhibitors

Enanta Pharmaceuticals describes FXR agonists

Norgine reports results from phase III DAYB study of Plenvu

Celon Pharma develops PI3Kdelta inhibitors

Arisan Therapeutics presents RNA polymerase inhibitors

[18F]PSMA-1007: a promising new F-18-labeled PSMA-targeting PET tracer

In vivo results of the novel PDE4D-sparing PDE4 PET radioligand [18F]PF-06445974

Phase I study shows feasibility of combining lurbinectedin and capecitabine

Leukemia & Lymphoma Society announce launch of Beat AML Master Trial

FDA approves Tecentriq for metastatic NSCLC

HiberGene announces launch of HG Group B Streptococcus direct swab test

KemPharm enters agreement with Acura Pharmaceuticals for Aversion technology

Spero Therapeutics receives DoD award for anti-infective potentiator program

Novel targeted alpha radiotherapeutic shows potential for prostate cancer

ContraVir Pharmaceuticals begins enrollment of next dosing group in phase IIa trial of CMX-157

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....